C115 - Emerging Approaches to Biosensing for the Diagnosis and Management of Neurological Disease
| Event Time: | Monday May 6, 2019 3:30 pm to 5:30 pm |
| Topic(s): | General Neurology |
| Director(s): | John Hixson MD |
| Description: | Mobile technologies for detecting and storing physical variables relevant to neurologic disease are advancing at a rapid pace. The data collected through these devices promises to aid in both diagnosis and management. By focusing on the uses of wearable and mobile phone applications for a variety of neurologic conditions, faculty with facilitate a discussion about the potential applications, benefits, and drawbacks. |
| Completion Message: | Participants should become familiar with the variety of wearable and mobile phone-based technologies that may provide value to neurologists and neurology patients. Additionally, participants should be able to recognize the potential benefits, as well as the challenges and pitfalls in this space. |
| CME Credits: | 2 |
| Core Competencies: | Patient Care, Medical Knowledge |
| Start/End Time | Title | Faculty |
|---|---|---|
| 3:30 PM - 3:35 PM | Introduction to Biosensing in Neurology | John David Hixson MD |
| 3:35 PM - 4:00 PM | Updates on Wearables for Epilepsy Care | Rosalind Picard ScD |
| 4:00 PM - 4:10 PM | Questions and Answers | Rosalind Picard ScD |
| 4:10 PM - 4:40 PM | Biosensing in Parkinson's Disease | E. Ray Dorsey MD, MBA, Suchi Saria PhD |
| 4:40 PM - 4:50 PM | Questions and Answers | E. Ray Dorsey MD, MBA, Suchi Saria PhD |
| 4:50 PM - 5:25 PM | Biosensing in Multiple Sclerosis | Jennifer Graves MD, PhD |
| 5:25 PM - 5:30 PM | Questions and Answers | Jennifer Graves MD, PhD |
| Speaker | Disclosure |
|---|---|
| E. Ray Dorsey, MD, MBA | Dr. Dorsey has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with 23andMe, Abbott, Abbvie, American Well, Biogen, Clintrex, DeciBio, Denali Therapeutics, GlaxoSmithKline, Grand Rounds, Karger, Lundbeck, MC10, MedAvante, Medical-legal services, Mednick Associates, National Institute of Neurological Disorders and Stroke, Olson Research Group, Optio, Prilenia, Putnam Associates, Roche, Sanofi, Shire, Sunovion Pharma, Teva, UCB, Voyager Therapeutics. Dr. Dorsey has received personal compensation in an editorial capacity for Karger Publications. Dr. Dorsey has received research support from Abbvie, Acadia Pharmaceuticals, AMC Health, Biosensics, Burroughs Wellcome Fund, GlaxoSmithKline, Nuredis Pharmaceuticals, Pfizer, Prana Biotechnology, Raptor Pharmaceuticals, Roche, and Teva Pharmaceuticals. |
| Jennifer Graves, MD, PhD | Dr. Graves has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Celgene. Dr. Graves has received research support from Biogen. |
| John David Hixson, MD | Dr. Hixson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Neurelis, UCB Inc., Grand Rounds, and Lumetra Healthcare Solutions. Dr. Hixson has received personal compensation in an editorial capacity for AANnews. Dr. Hixson has received research support from UCB Inc.. |
| Rosalind Picard, ScD | Dr. Picard has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Empatica, InterSystems, EMDMillipore, and Deloitte. Dr. Picard has received royalty, license fees, or contractual rights payments from Affectiva. Dr. Picard holds stock and/or stock options in Empatica. Dr. Picard has received research support from over 90 companies that are members of the MIT Media Lab. |